The Latest Cardiac and Vascular News
Marks 7th Regulatory Approval for VASCEPA®/VAZKEPA® Franchise in Key International Markets Since 2022 DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced that Medsafe in New Zealand has granted approval to VAZKEPA (icosapent ethyl) to reduce the risk of cardiovascular (CV) events […]
Highlights Significant Board Refreshment, Operational and Financial Improvements and Engagement with Sarissa Capital Management DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 11, 2023 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) (“Amarin” or the “Company”) today confirmed receipt of a requisition by Sarissa Capital Management LP (“Sarissa”) to convene a General Meeting […]
— Company Delivers Fourth Consecutive Quarter of U.S. Revenue Stabilization, Positive Fourth Quarter Cash Flow and Continued Progress on European Reimbursements — — Amarin to Present at 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023 — DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 10, 2023 (GLOBE NEWSWIRE) — Amarin […]
— Amarin Continuing Process for Obtaining National Pricing and Reimbursement in Switzerland in the Course of 2023 — — Swissmedic Approval Underpins Company’s Presence and Expansion in Switzerland as its Regional Commercial Hub for Europe — DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 07, 2022 (GLOBE NEWSWIRE) — Amarin Corporation plc […]
— VAZKEPA® Approved in Australia to Reduce the Risk of CV Events in Adult Statin-Treated Patients with High CV Risk with Elevated Triglycerides — — Marks Fifth Regulatory Approval for VASCEPA®/VAZKEPA® Franchise in Key International Markets in 2022 — DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 15, 2022 (GLOBE NEWSWIRE) — […]
— Independent RESPECT-EPA Study Now Third in a Series of Trials to Underscore CV Risk Reduction Benefits of Eicosapentaenoic Acid for Patients — — PROMINENT Study Failed to Show CV Risk Reduction Benefit of the Fibrate Class for Statin-Treated High-Risk Patients — DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 07, 2022 […]
— U.S. Business Trends Stabilize and Progress on Operational Initiatives Result in Extended Cash Runway — — Commenced Launch of VAZKEPA® (icosapent ethyl) in England & Wales Mid-October As Planned – — Obtained Positive Scientific Assessment for Reimbursement in Italy and the Netherlands & Achieved Positive National Reimbursement in Finland […]
Lars Ekman and Patrick O’Sullivan to Retire from Amarin Board at year-end New Independent Directors Bring Significant International Experience in Healthcare and Finance Seventy-five Percent New Independent Directors Appointed Over Last Twelve Months Amarin Continues Active Board Refreshment Program DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) — […]
— Data Show VASCEPA/VAZKEPA Significantly Reduced First and Total Cardiovascular Events in Combined Current and Former Smokers by 23% and 29% Respectively Relative to Placebo in a Post Hoc Analysis — –– Data Presented as an Oral Abstract at European Society of Cardiology (ESC) Congress 2022 in Barcelona and Published in EHJ Cardiovascular […]
— Late-Breaking Data Show VASCEPA/VAZKEPA Significantly Reduced STEMI by 40% and NSTEMI by 27% in Pre-Specified, Post Hoc Analyses — — Data Presented During Late-Breaking Science Session at European Society of Cardiology (ESC) Congress 2022 in Barcelona — DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 26, 2022 (GLOBE NEWSWIRE) — Amarin […]
